Korea Republic Of

SK Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

Interphex

Participation Not Confirmed

Update your events

SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenobamate in Japan

Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Xcopri

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Ono Pharmaceutical

Deal Size: $506.0 million Upfront Cash: $47.0 million

Deal Type: Licensing Agreement October 13, 2020

Details:

SK Biopharmaceuticals will conduct a Phase 3 clinical study for partial-onset seizures in adults in Northeast Asia (Japan, China, and Korea). In addition, SK Biopharmaceuticals has an option for co-promotion with Ono in the Japanese market.

SK Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

Interphex

Participation Not Confirmed

Update your events

SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Xcopri

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 10, 2020

Details:

The Phase 3 trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of cenobamate as an adjunctive therapy in subjects with partial-onset seizures, with an optional open-label extension.

SK Biopharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

Interphex

Participation Not Confirmed

Update your events

SK Biopharmaceuticals Set to Make Historic IPO

Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Xcopri

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $800.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 19, 2020

Details:

SK Biopharmaceuticals Co Ltd priced its initial public offering on Friday at the top of its indicative range, aiming to raise 959 billion won ($794 million) in South Korea's biggest IPO in three years.